Dividend reinvestment boosts GSK (NYSE: GSK) executive and director holdings

Rhea-AI Filing Summary

GSK plc reports that multiple senior executives and non-executive directors increased their holdings in its equity through dividend reinvestment plans. On 9 April 2026, cash dividends were reinvested into Ordinary Shares and American Depositary Shares held in the Company’s Deferred Annual Bonus Plan, a pension plan, or directly.

On 14 April 2026, CEO Luke Miels received a notional increase of 1,178 Ordinary Shares at £21.6700, and CFO Julie Brown received 1,553 Ordinary Shares at £21.6700. Other executives, including the Chief People Officer, Chief Digital and Technology Officer, and President, Corporate Development, received smaller Ordinary Share or ADS allocations at similar prices.

Several independent non-executive directors, such as Charles Bancroft and Dr Hal Barron, acquired modest amounts of ADS (for example 313 ADS at $58.9307) via dividend reinvestment on the New York Stock Exchange. These are plan-based acquisitions rather than open-market trading decisions.

Insights

Equity compensation and governance analyst

Plan-based dividend reinvestments modestly raise GSK insider holdings.

Named executives and directors at GSK received additional Ordinary Shares and ADS through dividend reinvestment within deferred bonus and pension arrangements. Transactions such as 1,178 Ordinary Shares for the CEO at £21.6700 are compensation-plan mechanics, not discretionary buying.

Because all transactions are acquisitions tied to a declared dividend on 9 April 2026, they carry weaker signalling value than open-market purchases. They do, however, marginally increase insider exposure to GSK equity across leadership and the board.

Future company filings may show how these plan-based accruals contribute to longer-term alignment between management, directors and shareholders as additional dividends are reinvested over time.

Key Figures

CEO dividend-reinvested Ordinary Shares: 1,178 shares at £21.6700 CFO dividend-reinvested Ordinary Shares: 1,553 shares at £21.6700 Chief People Officer ADS: 11.357 ADS at $58.3499 +3 more

6 metrics

CEO dividend-reinvested Ordinary Shares 1,178 shares at £21.6700 Luke Miels, transaction date 14 April 2026

CFO dividend-reinvested Ordinary Shares 1,553 shares at £21.6700 Julie Brown, transaction date 14 April 2026

Chief People Officer ADS 11.357 ADS at $58.3499 Diana Conrad, acquisition under GSK pension plan on 13 April 2026

Chief Digital & Technology Officer ADS 600.819 ADS at $59.1703 Shobie Ramakrishnan, dividend reinvestment on 14 April 2026

Charles Bancroft ADS 313 ADS at $58.9307 Senior Independent Non-Executive Director, 9 April 2026

ADS reinvestment batch 308 ADS at $58.3600 Shobie Ramakrishnan, ADS in Deferred Annual Bonus Plan on 14 April 2026

Key Terms

PDMR, Deferred Annual Bonus Plan, American Depositary Shares, LEI, +2 more

6 terms

PDMR regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

Deferred Annual Bonus Plan financial

"Ordinary Shares held in the Company's Deferred Annual Bonus Plan"

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares ('ADS')"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

LEI regulatory

"LEI | 5493000HZTVUYLO1D793"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

notional interest financial

"Increase in notional interest in Ordinary Shares following the re-investment of dividends"

dividends paid to shareholders financial

"following the re-investment of dividends paid to shareholders on 9 April 2026"

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.6700	232
			£21.6700	630
			£21.6700	316
		d)	Aggregated information
Aggregated volume Price	1,178 £21.6700
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.6700	458
			£21.6700	589
			£21.6700	506
		d)	Aggregated information
Aggregated volume Price	1,553 £21.6700
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.6700	132
			£21.6700	132
			£21.6700	334
		d)	Aggregated information
Aggregated volume Price	598 £21.6700
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.6700	109
			£21.6700	339
			£21.6700	205
		d)	Aggregated information
Aggregated volume Price	653 £21.6700
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 9 April 2026 on ADSs held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.3600	53
			$58.3600	96
			$58.3600	159
		d)	Aggregated information
Aggregated volume Price	308 $58.3600
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.6700	161
			£21.6700	401
			£21.6700	183
		d)	Aggregated information
Aggregated volume Price	745 £21.6700
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.6700	169
			£21.6700	483
			£21.6700	268
		d)	Aggregated information
Aggregated volume Price	920 £21.6700
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.6700	117
			£21.6700	163
			£21.6700	270
		d)	Aggregated information
Aggregated volume Price	550 £21.6700
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.6700	154
			£21.6700	418
			£21.6700	252
		d)	Aggregated information
Aggregated volume Price	824 £21.6700
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.6700	215
			£21.6700	235
			£21.6700	515
		d)	Aggregated information
Aggregated volume Price	965 £21.6700
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Elizabeth McKee Anderson
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.9307	26
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Charles Bancroft
b)	Position/status	Senior Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.9307	313
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.9307	26
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Anne Beal
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.9307	32
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Harry Dietz
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneeror auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.9307	30
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Jeannie Lee
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.9307	14
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Vishal Sikka
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.9307	96
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.1703	270.573
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ​ ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.1703	292.894
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ​ ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.3600	151.897
		d)	Aggregated information	N/A (single transaction)
			Aggregated volume Price
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ​ ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.1703	600.819
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-14
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ​ ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS under GSK pension plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.3499	11.357
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: April 16, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider share transactions did GSK (GSK) report in this Form 6-K?

GSK reported multiple insider share acquisitions by executives and directors driven by dividend reinvestment. Ordinary Shares and ADS were added to holdings in deferred bonus and pension plans, as well as directly, following dividends paid on 9 April 2026 at specified pound and dollar prices.

How did GSK’s CEO and CFO increase their share interests in April 2026?

CEO Luke Miels received a notional increase of 1,178 Ordinary Shares at £21.6700, while CFO Julie Brown received 1,553 Ordinary Shares at £21.6700. Both changes arose from reinvestment of the 9 April 2026 dividend within GSK’s Deferred Annual Bonus Plan, not open-market purchases.

Which GSK insiders acquired American Depositary Shares (ADS) via dividend reinvestment?

Several GSK insiders, including Shobie Ramakrishnan, Elizabeth McKee Anderson and Charles Bancroft, acquired ADS on the NYSE through dividend reinvestment. For example, Bancroft received 313 ADS at $58.9307 and Ramakrishnan received 600.819 ADS at $59.1703, reflecting automatic plan-driven allocations.

Were GSK’s April 2026 insider transactions open-market buys or plan-based?

The reported transactions are plan-based acquisitions linked to dividend reinvestment and a pension plan. Descriptions state increased notional interest or acquisition of shares and ADS following the 9 April 2026 dividend, indicating automated application within GSK’s compensation and savings arrangements, not discretionary market trades.

On what dates and exchanges did GSK insiders’ April 2026 transactions occur?

Most Ordinary Share transactions were dated 14 April 2026 on the London Stock Exchange (XLON). ADS-related transactions occurred on 9, 13 and 14 April 2026 on the New York Stock Exchange (XNYS), all tied to reinvestment of the dividend paid on 9 April 2026.

What is GSK’s Deferred Annual Bonus Plan mentioned in these transactions?

The Deferred Annual Bonus Plan is a GSK arrangement where part of executives’ bonuses is held in company equity. In April 2026, dividends paid on Ordinary Shares or ADS in this plan were automatically reinvested, increasing executives’ notional interests without requiring separate market purchases.